PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Automated Liquid Handling to Advance 3D Cell Culture

3D cell culture technology is rapidly gaining traction in drug discovery workflows, in particular for in vitro testing and simulation of disease progression and therapeutic response. Adding further momentum is the recent introduction of the UK roadmap to phase out animal testing with organon-a-chip and organoid methodologies set to become a critical aspect of many preclinical testing protocols.1 Building on the original 3Rs principle of Replacement, Reduction, and Refinement, efforts are shifting to introduce non-animal-based methods into research.

By bridging the gap between in vitro and in vivo models, 3D cell cultures can provide fundamental information on cellular functions, signalling pathways, and nuclear activities. Through accurately mimicking human tissue-like structures, 3D models provide a better representation of the in vivo environment, than traditional 2D cell cultures, and can therefore provide useful predictive insights into in vivo responses to drug treatment. However, 3D models are not yet widespread in preclinical testing, often hindered by limitations associated with their development and standardisation. Overcoming these challenges will require innovative solutions to reduce variability and increase reproducibility before 3D models can be adopted as standard.

3D Models to More Accurately Model In Vivo Conditions

3D models offer significant advantages over traditional 2D cell models, increasing cell-to-cell contacts and allowing the culture to grow and interact with the surrounding extracellular environment, more accurately reflecting living tissue (Figure 1.).

The very first example of a 3D cell model was in 1970, when Sutherland and colleagues developed a multicellular spheroid culture to create a functional phenotype of cancer cells, and then used the model to evaluate these cells’ response to radiotherapy. Spheroids are simple cellular aggregates that contain both internal and external layers of cells with varying exposure to the external environment, simulating the gradient of nutrients and oxygen seen in in vivo conditions.

The next phase of 3D cell culturing included organoids: more complex structures than spheroids, offering a simplified model system of organs that better reflect organ architecture and functionality.4 Further to this, researchers developed organ-on-a-chip, the most advanced model-type to date that mimics the activities, mechanisms, and physiological processes of organs and organ systems, and has the potential to replace animal models in drug testing studies (Figure 2.).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026